Agenus Inc news

   Watch this stock
Showing stories 1 - 10 of about 84   

Articles published

AGEN 3.92 -0.07 (-1.67%)
price chart
Why Agenus Inc. Shares Tumbled
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
GSK's MAGE-A3 Cancer Immunotherapeutic Phase 3 Study in Non-Small Cell ...  Business Wire (press release)
Agenus stock falls as partner GSK misses goals in lung cancer trial  Boston Business Journal (blog)
Related articles »  
Why Agenus Inc. Stock Skyrocketed
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
Agenus Rallies On Brain Cancer Vaccine Results  Bidness Etc
Agenus Brain Cancer Vaccine Shows Extended Survival in Phase 2 Final Data ...  Business Wire (press release)
Related articles »  
Premarket Movers, December 18: Tetraphase Pharmaceuticals Inc (TTPH ...
Cerulean Pharma Inc (NASDAQ:CERU), -3.38%, as the company announced yesterday that the first patient has been given a dose of CRLX301 (nanoparticle-drug conjugate) in a phase 1/2a trial, that is being conducted for individuals with advanced solid ...
Why Agenus Inc. Stock Briefly Spiked Higher
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
Maxim Keeps Agenus (AGEN) at Buy, Comments on HerpV Phase 2 Results  StreetInsider.com (subscription)
UPDATE: Agenus Vaccine Shows Significant Reduction in Viral Burden after ...  Benzinga
Related articles »  
Agenus Inc - A Potential New Play On Ebola
Shares of Agenus Inc (NASDAQ: AGEN) have moved to the upside in Monday's trade as the company is being mentioned as a potential play on Ebola.
Related articles »  
Agenus Inc.: Ingeniously Designed Vaccines To Galvanized Tomorrow's Medicine
Agenus Inc. (AGEN), headquartered in Lexington, Massachusetts, is an immune-oncology biopharmaceutical company focused on the development of innovative technologies and products aimed at treating cancers and infectious disease by helping the ...
Related articles »  
Form 8-K AGENUS INC For: Dec 18
Agenus Inc. today announced that GlaxoSmithKline's ZOE-50 Phase 3 studyi evaluating the efficacy of HZ/suii, which contains Agenus'QS-21 Stimulon´┐Ż adjuvant, for the prevention of shingles met its primary endpoint. Analysis of the primary endpoint ...
Trader's Buzz: Agenus Inc. (NASDAQ:AGEN), Olympic Steel Inc. (NASDAQ ...
On 11 December, Agenus Inc. (NASDAQ:AGEN) said that Ludwig Cancer Research announced an agreement with Agenus that grants the Lexington, MA-based biotechnology company exclusive license to further develop and commercialize antibodies ...
HC Wainright Reiterates $6.00 Price Target for Agenus (AGEN)  Dakota Financial News
Related articles »  
Agenus Inc. (AGEN) Buy Rating Reiterated at H.C. Wainwright
H.C. Wainwright reiterated a Buy rating on Agenus Inc. (NASDAQ: AGEN) with a price target of $6.00. Comments follow phase 2 Prophage data.
UTHSC Tests Agenus Inc.'s New Immune Boosting Melanoma Therapies
Agenus Inc. has announced the initiation of the Phase 2 clinical trial at the University of Texas Health Science Center at Houston to test its immune boosting melanoma drugs.
Related articles »